However, in this case, fedratinib therapy (200 mg a day owing to JAK2 pathogenic gene variants) was continued because, initially, the association between fedratinib and uveitis was unclear, and fedratinib was effective for splenomegaly. This evidence concerns the gene JAK2 and uveitis.